Medtech Connect Episode 4: Intelligent Devices
Executive Summary
In this episode of Medtech Connect, Medtech Insight regulatory reporter Hannah Daniel interviews, Kelliann Payne, partner at Hogan Lovells. Payne advises artificial intelligence (AI) medical device manufacturers with premarket submissions and helps them navigate the complicated regulatory landscape. She laid out the current FDA regulations for AI medical devices and explained the importance of predetermined change control plans, a new cyber regulation from the Consolidated Appropriations Act of 2023.
You may also be interested in...
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.
Joint AI/ML Risk Management Guidance Brings FDA Standard To UK
A collaborative document by a US and British organizations brings FDA-approved AI/ML risk management standards to the UK.
FDA Encourages Voluntary Device Shortage Reporting After PHE End
The FDA updated its policies regarding 506J notifications for device manufacturers at the end of the public health emergency.